This clinical investigation, denominated the ARROW study, was designed to rigorously evaluate pralsetinib’s long-term clinical benefits and safety profile. Unlike conventional chemotherapies with broad cytotoxic effects, pralsetinib specifically targets RET kinase activity, disrupting tumor cell signaling cascades pivotal for cancer cell survival and proliferation. The study embraced a cohort of 281 patients diagnosed with advanced or metastatic RET fusion-positive NSCLCs, including subgroups that were treatment-naive, those who had undergone previous chemotherapy, and individuals with brain metastases. This extensive patient population allowed for a comprehensive assessment of the drug’s efficacy across diverse clinical landscapes.

What distinguishes pralsetinib from earlier therapeutic approaches is its precision in intercepting the aberrant gene fusion pathways. RET fusions arise predominantly with partner genes such as CCDC6 and KIF5B, resulting in constitutively active chimeric proteins that drive malignant transformation. Intriguingly, the study revealed variation in therapeutic durability based on fusion partner type; patients exhibiting the CCDC6-RET fusion demonstrated a striking median duration of response stretching nearly four years, a stark contrast to the markedly shorter 13.1 months observed in those with KIF5B-RET fusions. This nuanced understanding underscores the complex biology underpinning RET-driven oncogenesis and hints at the potential for fusion-specific therapeutic strategies.

The response rates observed were equally compelling. Untreated patients witnessed an impressive overall response rate (ORR) of 78%, whereas individuals with prior chemotherapy exposure still achieved 63%. The efficacy extended into the challenging realm of brain metastases, a common complication in advanced lung cancer, where a 73% ORR was recorded. These figures not only emphasize pralsetinib’s robust antitumor activity but also its ability to penetrate the blood-brain barrier, a notorious obstacle in oncology drug development. Such advances accentuate the shifting paradigm in lung cancer treatment, tilting towards personalized medicine grounded in molecular pathology.

Closely scrutinizing the safety profile, pralsetinib demonstrated generally manageable toxicities, with anemia, hypertension, and neutropenia being the predominant adverse effects. While these side effects necessitated dose adjustments in more than half the patients and treatment discontinuation in a fraction, the overall tolerability of pralsetinib remained favorable. Notably, three patient deaths were attributed to treatment-related causes, highlighting the imperative for vigilant monitoring and supportive care. Importantly, unlike other RET inhibitors, pralsetinib did not provoke hypersensitivity reactions in patients previously treated with immunotherapies, a critical consideration given the expanding landscape of immuno-oncology.

The implications of this study extend beyond mere numbers. According to Dr. Justin Gainor, an expert in solid tumor oncology and senior author of the research, the prolongation of median overall survival to approximately 44 months signals a monumental leap forward for RET fusion-positive NSCLC patients. This outcome reflects not only pralsetinib’s potent antitumor efficacy but also the vital importance of early and comprehensive biomarker testing in clinical practice. Detecting RET fusions early can decisively guide personalized treatment choices, potentially transforming patient trajectories with tailored targeted therapies.

Moreover, the research underscores the evolving nature of resistance mechanisms against RET inhibition. Despite pralsetinib’s efficacy, cancer genomes are notoriously plastic, often evolving secondary mutations or activating bypass pathways that undermine therapeutic success over time. The identification and characterization of these resistance patterns remain a crucial frontier, enabling next-generation inhibitors and combination regimens to be developed, thereby sustaining durable remissions and potentially eradicating minimal residual disease.

The ARROW study’s methodology, encompassing an open-label, multi-center phase 1/2 design with a prolonged follow-up, provides a robust clinical framework. Such comprehensive data capture over an extended period allows for the nuanced assessment of both efficacy endpoints and adverse event profiles. This approach contrasts with short-term studies that may overlook chronic treatment effects or late-emerging toxicities, thus reinforcing the credibility and clinical relevance of the reported findings.

This groundbreaking work was the culmination of collaborative efforts from a multinational team of oncology specialists, including renowned figures such as Benjamin Besse, Vivek Subbiah, Giuseppe Curigliano, and others from leading institutions. Their collective expertise spans molecular oncology, clinical trial design, and cancer genomics, reflecting the multidisciplinary synergy required to tackle complex oncogenic drivers. The authorship also includes representatives affiliated with pharmaceutical industry partners, underscoring the critical role of industry-academia partnerships in drug development.

Looking forward, these findings invigorate the oncology community’s commitment to refining RET-targeted therapies and underscore the merit in exploring pralsetinib’s potential across other RET-driven malignancies. As precision oncology continues to evolve, integrating comprehensive genomic profiling with innovative targeted agents offers the promise of transforming cancer management from a one-size-fits-all model to a highly individualized and effective therapeutic strategy. Ultimately, patients facing the daunting diagnosis of RET fusion-positive NSCLC can now hold renewed hope for improved survival and quality of life thanks to such scientific advancements.

Subject of Research: People

Article Title: Final Efficacy and Safety Data From the Phase 1/2 ARROW Study of Pralsetinib in Patients With Advanced RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC)

News Publication Date: 27-Mar-2026

Web References:
Journal of Clinical Oncology DOI: 10.1200/JCO-25-01489

References:
Besse B et al. “Final Efficacy and Safety Data From the Phase 1/2 ARROW Study of Pralsetinib in Patients With Advanced RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC).” Journal of Clinical Oncology, DOI: 10.1200/JCO-25-01489.

Keywords:
RET fusion, non-small cell lung cancer, pralsetinib, targeted therapy, phase 1/2 clinical trial, ARROW study, lung cancer treatment, personalized oncology, brain metastases, RET inhibitors, fusion partners, cancer genomics

Lung cancer remains one of the deadliest malignancies globally, frequently complicated by the development of brain metastases, which significantly worsen patient outcomes. Traditional imaging methods, particularly craniocerebral magnetic resonance imaging (MRI), are the current standard for detecting BM, offering high sensitivity and detailed anatomical resolution. However, MRI’s ability to characterize metabolic activity or fibroblast activation within lesions is limited, necessitating adjunctive diagnostic tools.

The study prospectively enrolled 18 patients between December 2020 and October 2021, all of whom had histologically confirmed lung cancer and were clinically suspected of harboring brain metastases. Each patient underwent paired imaging with ^18F-FAPI PET/CT and craniocerebral MRI to facilitate a comparative analysis of detection rates. This concurrent imaging strategy enabled precise assessment of ^18F-FAPI PET/CT’s performance relative to the MRI gold standard.

^18F-FAPI PET/CT leverages a radiotracer targeting fibroblast activation protein (FAP), highly expressed in cancer-associated fibroblasts within the tumor microenvironment. This molecular imaging technique exposes the metabolic and stromal components of tumors, which may vary significantly among different cancer histologies. The study measured parameters including maximum and peak standardized uptake values (SUVmax and SUVpeak), alongside tumor-to-background ratios (TBR), to quantify tracer uptake and enhance lesion conspicuity.

Of the 76 BM lesions documented by MRI, only 23 were detected by ^18F-FAPI PET/CT, indicating variability in tracer affinity and imaging sensitivity. Remarkably, adenocarcinoma metastases exhibited the highest detection rate at 48.28%, significantly outperforming large cell carcinoma (16.67%) and small cell carcinoma, for which the detection rate was zero. Squamous carcinoma held an intermediate position with a 35.71% detection rate, not statistically different from adenocarcinoma.

These findings underscore the heterogeneous biological behavior of lung cancer subtypes. The high detection rate in adenocarcinoma may reflect greater fibroblast activation or elevated FAP expression within these lesions, enhancing ^18F-FAPI uptake. Conversely, the lack of detectability in small cell carcinoma suggests either low FAP expression or limited stromal reaction, rendering PET-based fibroblast-targeting ineffective for this subtype.

Statistical analyses demonstrated that squamous carcinoma’s detection rate was significantly superior to that of small cell carcinoma but showed no meaningful difference when compared to large cell carcinoma. Differences between large cell carcinoma and small cell carcinoma also lacked statistical significance. These comparative results highlight the complexity of tumor microenvironments and their impact on molecular imaging performance.

The study’s implications extend beyond diagnostic accuracy; by delineating the differential ^18F-FAPI PET/CT detection rates, clinicians may tailor surveillance and therapeutic interventions more effectively. Enhanced detection of brain metastases in adenocarcinoma patients may facilitate timely interventions, improving prognostication and potentially influencing survival outcomes.

Importantly, the integration of ^18F-FAPI PET/CT with conventional MRI could refine staging and treatment monitoring frameworks. The molecular insights provided by PET imaging complement structural MRI data, offering a dual modality approach that encompasses anatomical and pathophysiological tumor characteristics.

The research also opens avenues for exploring fibroblast activation as a therapeutic target or biomarker in lung cancer brain metastases. Understanding why certain subtypes exhibit robust FAP expression may inform the development of targeted therapies aimed at disrupting the tumor stroma or modifying the metastatic niche within the brain.

Methodologically, the prospective enrollment and paired imaging design enhance the reliability of findings. However, the relatively small sample size and limited number of metastases across subtypes may warrant larger-scale studies to validate these preliminary observations and elucidate underlying mechanisms with greater statistical power.

Future investigations might explore longitudinal imaging to evaluate changes in ^18F-FAPI uptake during treatment or disease progression, shedding light on tumor dynamics and treatment response. Additionally, correlating imaging results with histopathological assessments of FAP expression could deepen understanding of PET tracer specificity and sensitivity.

As the landscape of molecular imaging evolves, ^18F-FAPI PET/CT represents a promising modality for enhancing brain metastasis detection in lung cancer, particularly for adenocarcinoma patients. This technique enriches the diagnostic armamentarium, offering new dimensions in the metabolic and stromal evaluation of metastatic lesions.

Ultimately, this study contributes compelling evidence that varying pathological types of lung cancer differ markedly in their ^18F-FAPI PET/CT detection rates for brain metastases. These insights may herald a shift towards more personalized diagnostic and prognostic strategies, underscoring the critical role of tumor biology in imaging and clinical outcomes.

The research was conducted with institutional review board approval (NO. SDZLEC2021-112-02), affirming adherence to ethical standards. The authors, Li et al., invite further exploration of ^18F-FAPI PET/CT’s utility in broader oncologic contexts, potentially expanding its application in clinical practice.

As molecular imaging technologies advance, the integration of quantitative measures such as SUVmax, SUVpeak, and TBR will become essential to standardize assessments and optimize interpretation across diverse patient populations and tumor types.

In summary, this landmark study elucidates the heterogeneous detection capabilities of ^18F-FAPI PET/CT in brain metastases from lung cancer, with adenocarcinoma showing the highest and small cell carcinoma the lowest detectability. These findings advocate for a nuanced application of molecular imaging tailored to tumor pathology, with significant implications for clinical decision-making and patient management.

Subject of Research: The utility of ^18F-FAPI PET/CT imaging for detecting brain metastases in various pathological types of lung cancer.

Article Title: Different detection rates of brain metastasis in different pathological types of lung cancer by ^18F-FAPI PET/CT.

Article References:
Li, H., Li, P., Zhu, S. et al. Different detection rates of brain metastasis in different pathological types of lung cancer by ^18F-FAPI PET/CT. BMC Cancer 25, 1620 (2025). https://doi.org/10.1186/s12885-025-15078-9

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-15078-9